Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-6114 Safety and PK in PKU
NCT04256655Phase 1Withdrawn
- Sponsor
- Nestlé
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Replacement Enzymes
01
Overview
Phase 1, randomised, double-blind trial of CDX-6114 in phenylketonuria (PKU) (3 cohorts), sponsored by Nestlé. Primary endpoints: Incidence of Treatment-Emergent Adverse Events (AEs) at Day 14, Serum levels of CDX-6114 at Day 14 and 5 more. Planned start Dec 2020; status: withdrawn.
02
Drugs
CDX-6114
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT04256655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04256655.